TTI-237

DRUG2 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

NeoplasmsTumors

Phase 1

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

TerminatedNCT00195247

Wyeth is now a wholly owned subsidiary of PfizerNeoplasms

Start: 2005-05-31Target: 45Updated: 2007-03-26

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

TerminatedNCT00195325

Wyeth is now a wholly owned subsidiary of PfizerNeoplasms, Tumors

Start: 2005-08-31Target: 45Updated: 2007-03-26